inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL

During the 66th American Society of Hematology (ASH) Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari, University of Modena and Reggio Emilia, Modena, IT. We asked about the latest updates from the inMIND trial of tafasitamab plus lenalidomide and rituximab for R/R FL.

In this interview, Luminari shares data from the phase III inMIND (NCT04680052) trial of patients with relapsed/refractory follicular lymphoma treated with tafasitamab in combination with lenalidomide and rituximab. Luminari covers key outcomes, highlighting promising efficacy and safety data. He concludes that the data are encouraging and supports using this combination for patients with relapsed/refractory follicular lymphoma in the second-line setting.

This educational resource is independently supported by Incyte. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.